Clinical trials: Immunization
Influenza
Two-site Intradermal Influenza Vaccination in Elderly
One-site dose sparing intradermal influenza vaccination in elderly had been studied but resulted in unsatisfactory outcomes. The investigators evaluate the safety and immunogenicity of the two-site intradermal injection of…
- Trial name
- NCT01202552
- Testing
- seasonal influenza vaccine
- Where
- Thailand
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Pertussis
Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation
This study aims to establish an effective method to inform parents or close relatives of newborns about the risk of pertussis transmission to newborns and the advantages offered by the cocooning strategy (vaccinating those who…
- Trial name
- NCT01890447
- Testing
- Web-based survey questionnaire
- Where
- 9 sites in Italy, Spain
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue
Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome
Some people report persistent health problems after receiving the COVID-19 vaccine. These symptoms persist well beyond typical short-term vaccine side effects and are not attributable to any other known medical conditions.
- Trial name
- CLEAR (NCT07400848)
- Testing
- Blood sampling and analysis, The continuous Reactive Hyperemia Index (InRHI) measured by EndoPAT
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Bern
Vaccination
Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP
Eligible,healthy infants will be recruited and divided into 3 groups:(1)combined immunization of sIPV and DTaP group, (2) sIPV group and (3) DTaP group.
- Trial name
- NCT04053010
- Testing
- Sabin-IPV and DTaP, Sabin-IPV, DTaP
- Where
- China
- Volunteers
- 702 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19
Message Encouraging Vaccination in Preparation for the Holidays
This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned.
- Trial name
- NCT05612360
- Testing
- COVID Booster text messages
- Where
- United States
- Volunteers
- 520,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Yellow Fever
Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children
In a previous study by the researchers' group, the researchers' investigate the duration of yellow fever post-vaccination immunity in vaccinated children between 9 and 23 months of age.
- Trial name
- NCT02990182
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
HIV Infections
Extended Follow-Up of the ISS T-003 Trial Volunteers (ISS T-003 EF-UP2020)
A further extension of the follow-up of the volunteers of the ISS T-003 trial is being conducted in order to evaluate the persistence of vaccine immunogenicity as well as of the immunological and virological effects induced by…
- Trial name
- T003EFUP2020 (NCT05680948)
- Where
- South Africa
- Volunteers
- 179 people
- Sponsor
- Istituto Superiore di Sanità
Influenza, Human
Tropical Influenza Control Strategies for the Elderly
TROPICS1 is a randomized, observer-blind, active comparator-controlled, single-center, Phase IV trial in 200 participants aged ≥65 years.
- Trial name
- TROPICS1 (NCT02655874)
- Testing
- Influenza vaccine, Tetanus-diphtheria-pertussis vaccine
- Where
- Singapore
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Influenza Vaccination
Family Physician Nudges for Influenza Vaccination Among Older Adults
The goal of this clinical trial is to learn if a family-physician nudge intervention works to improve influenza vaccination among adults aged 65 years and older in China.
- Trial name
- NCT07864597
- Testing
- Family Physician Influenza Vaccination Nudge
- Volunteers
- 3,060 people, healthy volunteers welcome
- Sponsor
- Fudan University
Needle Fear, Vaccine Hesitancy
Thimble Mindfulness App and Recovery Patch Descriptions
The goal of this clinical trial is to lessen the pain and fear of needles by using a mindfulness-based app and a recovery patch on pediatric patients between the ages of 5 and 11.
- Trial name
- NCT05980247
- Testing
- Thimble Application
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bianca Edison
Malignant Melanoma
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
The purposes of this study are to describe the immune response to individual peptides after immunization with a combination of 8 peptides and CpG 7909 or Montanide ISA51; to determine the safety of the vaccines and; to document…
- Trial name
- NCT00145158
- Testing
- 8 HLA-A2-restricted peptides and Montanide ISA51, 8 HLA-A2-restricted peptides and CpG 7909
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Ludwig Institute for Cancer Research
Pertussis
2-year Follow-up After a Single Dose Acellular Pertussis Vaccination
In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccined) manufactured by BioNet-Asia Co., Ltd.
- Trial name
- NCT04113655
- Testing
- Pertagen (aP BioNet), Boostagen (TdaP BioNet), Adacel
- Where
- 2 sites in Thailand
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Meningococcal Infections
Regulation of Mucosal Immune Response to Systemic MenB Vaccine
Meningitis or septicaemia (blood poisoning) caused by group B meningococcal infection (MenB) is an important cause of death and disability in the UK. Prevention through vaccination therefore remains a key public health priority.
- Trial name
- NCT00774384
- Testing
- NZ MenB OMV vaccine (NZ98/254)
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Influenza, Virus Diseases
Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults
UMN-0501 is a purified recombinant influenza HA vaccine (A H5N1/Vietnam/1203/2004). The purpose of the present study is to evaluate immunogenicity, safety and optimal dose among three different doses of UMN-0501 following two…
- Trial name
- NCT00980447
- Testing
- UMN-0501
- Where
- 2 sites in Japan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Immunization; Infection|Transplantation Infection|Influenza, Influenza
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center.
- Trial name
- NCT07192458
- Testing
- Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center
Follicular Lymphoma, First Relapse/Progression
Idiotypic Vaccination for Follicular Lymphoma Patients
Poor prognosis follicular lymphoma patients have an estimated median overall survival of 5-6 years. The proposed trial offers life-time idiotypic vaccination to all such patients in first relapse/progression who will achieve…
- Trial name
- FLIDVAX2006 (NCT00530140)
- Testing
- Follicular lymphoma, patient-specific, soluble protein idiotype vaccine
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
COVID-19
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
This is a randomized, double-blind, active-controlled Phase Ⅲ clinical trial, as well as an immuno-bridging clinical trial by parallel testing previous serum after primary immunization of COVID-19 vaccine (Vero cell), inactivated…
- Trial name
- NCT05381350
- Testing
- COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant), COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)
- Where
- China
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
HIV-1 Infection
Lipopeptide Immunisation With GTU-multiHIV Trial
The combination of GTU-MultiHIV B DNA and LIPO-5 vaccines in a prime-boost strategy is expected to induce strong and diverse HIV-specific immune responses in HIV-infected patients.
- Trial name
- NCT01492985
- Testing
- GTU-multHIV B vaccine and LIPO-5 vaccine
- Where
- France
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19
Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination
Bacillus Calmette-Guérin (BCG) vaccine not only protects against tuberculosis, but has also been shown to induce protection against various infections with a viral aetiology, leading to significant reductions in morbidity and…
- Trial name
- NCT04417335
- Testing
- BCG vaccine
- Where
- 2 sites in Netherlands
- Volunteers
- 2,014 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Meningococcal Disease
Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants
To explore safety, Tolerability and immunogenicity of two formulations of a Meningococcal B Recombinant Vaccine when administered to healthy infants.
- Trial name
- NCT00433914
- Testing
- rMenB, rMenB+OMV
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.